Intract Pharma Email Format
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Based in London, England, Intract Pharma is a biotechnology company focused on the oral delivery of complex proteins, including monoclonal antibodies, for diseases driven by gastrointestinal and systemic immune-mediated inflammation. Through its Phloral and Soteria platforms, it aims to enable precision delivery of therapeutic proteins to the colon to achieve local tissue effects and systemic immunomodulation. The company’s objective is to transform how potent biologic medicines are administered, moving from injections to take-at-home oral formulations. Its target customers are pharmaceutical and biotechnology developers seeking new oral monoclonal antibody therapies for inflammatory indications, with the technology positioned as a platform for collaboration and licensing. Intract Pharma has engaged in multiple partnerships to apply its delivery technologies, including work with Celltrion, Bio-Thera Solutions, Elasmogen, and Tharimmune. In September 2024, Tharimmune announced an exclusive license with Intract Pharma for an oral anti-TNF monoclonal antibody candidate based on infliximab, illustrating active industry engagement.